During the 'Heart Failure and World Congress on Acute Heart Failure 2018', many sessions and lectures focused on cardio-oncology. This important field of research is constantly growing, and therefore, a great amount of time during the congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional lectures throughout the 'Heart Failure and World Congress on Acute Heart Failure 2018'. The covered topics included pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable with different circulating and imaging biomarkers, as well as cardioprotective treatments recommended by different guidelines and position papers.
Introduction
Cardio-oncology has become a large, expanding, and important translational research area in modern medicine, which is gaining rapid interest.
1,2
Unfortunately, chemotherapy, immunotherapy, radiation therapy, and targeted therapies do not only effect cancer cells but also effect cardiomyocytes and vascular cells.
3 This can result into minor, asymptomatic cardiac lesions, detectable with circulating biomarkers or strain echocardiography, and also into life-threatening conditions, like severe heart failure (HF) or fulminant myocarditis. 4,5 During the 'Heart Failure and World Congress on Acute Heart Failure 2018', three full scientific sessions as well as a number of additional lectures within broader-subject sessions were dedicated to cardiooncology. The sessions aimed to help improve the mechanistic understanding of cardiotoxicity as well as to help clinicians with practical advice and treatment strategies for cancer patients receiving potentially cardiotoxic oncology therapies. The congress was attended by 5881 participants with >300 faculty members from 47 countries and took place in Vienna, Austria, from May 26, 2018 , to May 29, 2018 . The first cardio-oncology session started from pathophysiological studies on the crosstalk of HF and cancer mechanisms and then addressed how to approach cardiotoxicity in cancer patients with preclinical markers of left ventricular dysfunction (LVD) and in patients with confirmed cardiotoxicity. The second session discussed the prevalence of cardiac dysfunction in cancer patients and the underlying mechanisms. The third session reviewed the current recommendations and gaps in evidence from the different cardio-oncology guidelines and position statements. Additional lectures addressed cardiomyopathy in cancer and the prevention of HF. Detailed listing of all sessions can be found in Table S1 .
Prevention and treatment of cardiotoxicity
In modern-day oncology, cardiotoxicity is a growing problem 1 and may be caused by cytotoxic chemotherapy, radiotherapy, molecular targeted therapies, and immune-modulating agents. In this scenario, active collaboration among different medical specialists is required to integrate cardiac imaging in cardio-oncology and to guide cardiovascular (CV) monitoring (Figure 1 ). Various definitions of CV toxicity exist depending upon the modalities used and whether clinical symptoms are required. Regarding direct myocardial toxicity, one common definition is a reduction of left ventricular ejection fraction (LVEF) by >10 percentage points and below the lower limit of normality (depending on local standard operating procedure 50-55% and identify new risk factors.
36,37
Thus, the prevention of HF in cancer patients is very important. Professor Alain Cohen-Solal from Paris, France, addressed a study conducted in 273 low CV risk adult cancer patients treated with low cumulative doses of anthracycline chemotherapy called 'The International CardioOncology Society-One' trial.
38 There were two arms in the study: in the first, enalapril was only administered during chemotherapy cycles if troponin levels increased, and in the second, enalapril was administered before and during the entire chemotherapy regime. With regard to the occurrence of cardiotoxicity, both strategies resulted in similar results. The authors concluded that the administration of enalapril may be suitable for patients with an increase of troponin values during anthracycline treatment, and Alain Cohen-Solal emphasized that quick initiation of CV treatment after detection of subclinical LVD is vital in cancer patients. 39 During a session on prevention of HF, Professor Dimitrios Farmakis addressed the interaction between HF and cancer, two entities that share several common risk factors, while the one seems to increase the risk and worsen the outcome of the other. Professor Farmakis grouped the strategies for the prevention of HF in cancer into three main categories, including 'primordial prevention' that is applicable before cancer therapy in patients without any evidence of CV abnormalities, 'primary prevention' during cancer therapy in the presence of subtle abnormalities such as increase in cardiac biomarkers or worsening of left ventricular global longitudinal strain, and 'secondary prevention' during or after cancer therapy in the presence of clear LVEF decline. All three approaches are important in preventing HF in cancer patients.
40
In the next congress presentation, Professor Thomas Suter from Bern, Switzerland, discussed the alternative clinical strategies to prevent cardiotoxicity. Professor Suter explained that in some cases, also non-anthracycline chemotherapies are an option, because these drugs are often associated with a lower chance of cardiotoxicity during treatment for high-risk patients but still can be effective in treating cancer.
1, 41 Furthermore, to reduce the likelihood of LVD and cardiotoxicity even further in some patients, he reviewed using liposomal doxorubicin or concomitant dexrazoxane (DEX). 1, 42 Newer options for cancer patients include targeted therapies like trastuzumab, which can also be associated with increased occurrence of cardiotoxicity. 43 Treatment duration of trastuzumab therapy is relevant to risk, and the benefit on HER2+ malignancies is significant and must be remembered when considering the risk:benefit balance.
44
The intersection between cardiology and oncology
In patients with HF, many different co-morbidities can influence the patients' burden of disease. 45, 46 Common 97 the potential cardioprotective effect of DEX in high-risk patients was positively documented, but its administration to cancer patients is associated with more frequent occurrence of leukopenia with respect to a meta-analysis. 98 Moreover, Cardinale et al.
14 demonstrated that prompt cardioprotective intervention with combination of ACE-inhibitors and beta-blockers is a possible option for recovery of LVEF after early detection of cardiac damage in echocardiograms. The recent position paper from the Heart Failure Association Cardio-oncology Study Group provides a contemporary review and framework for the patient with HF who develops cancer.
74
Markus Anker also discussed the neutral double-blind, placebo-controlled CECCY 99 trial that assessed the use of carvedilol for the prevention of anthracycline toxicity in a low CV risk cancer population and noted a short period of follow-up time in this trial. He concluded that future trials in cardio-oncology should have longer follow-up times, assess patients, who have a greater risk of cardiotoxicity, and test relevant (higher) doses of cardiotoxic chemotherapy.
Conclusions
During the 'Heart Failure and World Congress on Acute Heart Failure 2018', three sessions focused on the quickly growing field of cardio-oncology, along with some additional lectures during broader-themed sessions. The main focus of the sessions was how to recognize and treat cardiotoxicity in the clinical setting. More research including randomized clinical studies is needed to learn more about the prevention of cardiotoxicity and the long-term treatment of cancer patients with cardiac dysfunction. 
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